Latest News about IBB
Recent news which mentions IBB
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
From Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
From Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
February 15, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
From Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
February 11, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
From Benzinga
Biotech ETFs Muddled Despite Amgen Strength
February 08, 2022
From ETF Trends
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Small-Cap Biotech Opportunity Knocks
February 01, 2022
From ETF Trends
CNBC's Final Trades: NXP Semiconductors, Qualcomm, Deere And This Way To Gain Exposure To Growth Potential
February 01, 2022
From Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
From Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
3 Growth ETFs to Consider Buying During This Correction
January 29, 2022
From Motley Fool
Why Sorrento Therapeutics Stock Is Getting Hammered This Week
January 28, 2022
From Motley Fool
From Benzinga
From MarketWatch
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
January 27, 2022
From Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
January 26, 2022
From Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
January 25, 2022
From Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
From Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
From Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
From Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.